PerkinElmer Expands Presence In Asia With Acquisition Of SYM-BIO
This article was originally published in PharmAsia News
Executive Summary
PerkinElmer's acquisition of Shanghai-based diagnostics company SYM-BIO for $63.7 million will enhance the firm's diagnostics market position in China